Jade Biosciences/$JBIO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Jade Biosciences

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Ticker

$JBIO
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Waltham, United States

Employees

30

ISIN

US0080642061
Website
jadebiosciences.com

Jade Biosciences Metrics

BasicAdvanced
$338M
-
-$18.79
-
$84.00
801.53%

Bulls say / Bears say

Jade Biosciences completed a reverse merger with Aerovate Therapeutics and secured approximately $300 million in financing, providing a cash runway through 2027. (jadebiosciences.com)
The company's lead candidate, JADE101, is expected to enter first-in-human clinical trials in the second half of 2025, with interim data anticipated in the first half of 2026. (jadebiosciences.com)
Jade Biosciences has attracted investment from a syndicate of healthcare investors, including Fairmount, Venrock Healthcare Capital Partners, and others, indicating strong market confidence. (jadebiosciences.com)
As of March 31, 2025, Jade Biosciences reported a net loss of $38.2 million for the first quarter, reflecting high operational expenses. (jadebiosciences.com)
The company's stock price has experienced volatility, with a 52-week range between $1.25 and $25.29, indicating potential instability. (stockanalysis.com)
Jade Biosciences' lead candidate, JADE101, is still in preclinical development, and any delays or failures in clinical trials could negatively impact the stock. (jadebiosciences.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.

Jade Biosciences News

AllArticlesVideos
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

GlobeNewsWire·2 weeks ago
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

GlobeNewsWire·3 weeks ago
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JBIO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs